Glaxo to let Mylan make generic Paxil

All right, already. So says GlaxoSmithKline to Mylan Pharmaceuticals, which has been fighting the company's patent on extended-release Paxil, an antidepressant. Glaxo gave Mylan the patent licenses that allow it to sell Paxil ER beginning in October 2008. Mylan got FDA approval for its version of the drug in June, and it'll have 180-day exclusivity once it starts selling.

- see Mylan's press release
- check out the report from CNN Money

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.